Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men



Status:Recruiting
Conditions:Endocrine
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - 65
Updated:11/18/2018
Start Date:July 5, 2017
End Date:April 30, 2019

Use our guide to learn which trials are right for you!

A 12-Month, Randomized, Active-controlled, Open-label Study of the Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men (RE-TUne)

This will be a randomized, multicenter, open-label, active-controlled, efficacy, and safety
study in adult hypogonadal men. The study duration is 12 months (365 days), including a
90-day, open-label efficacy period and a 9-month (275-day) safety evaluation period.


Inclusion Criteria:

1. Male aged 18 to 65 years, inclusive, at the time of providing informed consent to
participate in the study.

2. Hypogonadism defined as having 2 consecutive serum total T levels≤ 281 ng/dL based on
a blood sample, drawn at least 3 days apart, between 7 a.m. and 10 a.m.

3. At least 1 clinical feature consistent with male hypogonadism. If a subject is
receiving commercial TRT prior to Screening Visit 1, he must have a history of at
least 1 clinical feature consistent with male hypogonadism.

4. Must be naïve to androgen replacement therapy or washed out adequately of prior
androgen replacement therapies; willing to cease current T treatment; or currently not
taking any T treatment. Subjects must remain off all forms of T, except for dispensed
study drug, throughout the entire study.

5. No unstable ongoing concomitant medical conditions. Treated and well-controlled
conditions such as type 2 diabetes, hypertension, or dyslipidemia are acceptable with
stable medication in place for at least 3 months prior to study entry:

1. Hemoglobin A1c ≤ 8.0%

2. BP < 150/90 mm Hg

3. Low-density lipoprotein cholesterol < 190 mg/dL.

6. Subjects with an endocrine disorder requiring treatment other than hypogonadism must
be on a stable dose of replacement medication for at least 3 months prior to study
entry.

7. Adequate venous access to allow collection of a number of blood samples via a venous
cannula.

8. Written informed consent to participate in the study and ability to comply with all
study requirements.

Exclusion Criteria:

1. Serum PSA > 2.5 ng/ml and/or abnormal prostate gland on palpation, eg, palpable nodes,
at Screening Visit 2.

2. Received oral, topical, intranasal, or buccal T therapy within the previous 2 weeks,
intramuscular T injection of short-acting duration within the previous 4 weeks,
intramuscular T injection of long-acting duration within the previous 20 weeks, or T
implantable pellets within the previous 6 months.

3. Use of any drug that could interfere with measurement or assessment of serum androgen
levels, including 5 alpha-reductase inhibitors, anabolic steroids, and drugs with
antiandrogenic properties (eg, spironolactone, cimetidine, flutamide, bicalutamide,
and ketoconazole). These drugs must be stopped for at least 1 month prior to study
entry (6 months in the case of dutasteride). Patients taking potent, long-acting
opiate therapy on a daily basis are not eligible for the study. Conversely, ad hoc use
of potent, short-acting opiates for a period of less than 7 days may be permitted
after discussion with the Marius Pharmaceuticals medical monitor.

4. Use of over-the-counter products, including natural health products (eg, food
supplements and herbal supplements such as saw palmetto or phytoestrogens) that may
affect total T levels, within 7 days prior to study entry.

5. History of drug or alcohol abuse within the past 2 years that in the opinion of the
investigator could interfere with study participation and/or influence study efficacy
and safety endpoints assessments.

6. Unstable or chronic disease that could interfere with participation in the study or
patient safety, including psychiatric disorders.

7. Myocardial infarction, coronary artery surgery, heart failure, stroke, unstable
angina, or other unstable cardiovascular disease within the past 6 months.

8. Abnormal ECG considered clinically significant by investigator at Screening.

9. Diagnosis of any cancer within the previous 5 years other than basal or squamous cell
skin cancer with clear margins.

10. Any surgical or medical condition that might alter administration of the study drug or
comparator, including history of gastric surgery, cholecystectomy, vagotomy, bowel
resection, or any surgical procedure that might interfere with gastrointestinal
motility, pH, or absorption of TU.

11. Duodenal or gastric ulcers, or gastrointestinal/rectal bleeding during the 3 months
prior to screening.

12. Chronic skin conditions on the chest or upper arms that would prevent administration
of AndroGel in a manner designed to ensure reliable and consistent absorption thereof.

13. Human immunodeficiency virus (HIV) infection.

14. Chronic hepatitis B virus and/or hepatitis C virus (HCV) infection (as determined by
positive testing for hepatitis B virus surface antigen or HCV antibody with
confirmatory testing, ie, detectable serum HCV ribonucleic acid [RNA]).

15. Clinically significant abnormal laboratory values at screening including but not
limited to:

1. Elevated liver enzymes (aspartate aminotransferase [AST], alanine
aminotransferase [ALT] > 2x upper limit of normal)

2. Estimated glomerular filtration rate < 60 ml/min/1.73m2 as calculated by the
Modification of Diet in Renal Disease formula

3. Hemoglobin < 12.5 g/dL.

16. Hematocrit > 48%.

17. Severe and untreated obstructive sleep apnea syndrome.

18. Severe lower urinary tract symptoms (American Urological Association/ IPSS ≥ 19).

19. History of seizures or convulsions, including febrile, alcohol, or drug withdrawal
seizures.

20. History of any clinically significant illness, infection, or surgical procedure within
1 month prior to study entry.

21. Past, current, or suspected prostate or breast cancer.

22. History of long QT syndrome or unexplained sudden death in a first-degree relative
(parent, sibling, or child).

23. Concurrent treatment with medications that may impact the absorption, distribution,
metabolism, or excretion of TU or place the subject at risk for treatment with T.

24. Subject has a partner who is currently pregnant or planning pregnancy during the
course of the study.

25. Treatment with any other investigational drug within 30 days of study entry or < 5
half-lives (whichever is longer) and at any time during the study.

26. History of noncompliance to medical regimens or potential unreliability in the opinion
of the investigator.

27. Unwilling or unable to comply to the dietary requirements for this study.

28. History of polycythemia, either idiopathic or associated with TRT.

29. Donated blood (≥ 500 mL) within the 12-week period prior to study entry.

30. History of an abnormal bleeding tendency or thrombophlebitis within the previous 2
years that is not linked to venipuncture or intravenous cannulation.

31. Onset of gynecomastia within the previous 6 months.
We found this trial at
41
sites
1905 Skibo Road
Fayetteville, North Carolina 28314
Principal Investigator: Daniel Uba
Phone: 910-864-4357
?
mi
from
Fayetteville, NC
Click here to add this to my saved trials
2950 Halcyon Ln # 706
Jacksonville, Florida 32223
Principal Investigator: Roger Miller
Phone: 904-880-1366
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
400 Gresham Dr
Norfolk, Virginia 23507
757-627-7446
Principal Investigator: Duane Wombolt
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
104 SE 1st Avenue
Ocala, Florida 34471
352-629-5800
?
mi
from
Ocala, FL
Click here to add this to my saved trials
7940 Floyd Curl Dr.
San Antonio, Texas 78229
210-949-0122
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Atlanta, Georgia 30312
Principal Investigator: Courtney Shelton
Phone: 678-705-2355
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Aventura, Florida 33180
Principal Investigator: Marc Gittelman
Phone: 305-931-8080
?
mi
from
Aventura, FL
Click here to add this to my saved trials
Bala-Cynwyd, Pennsylvania 19004
Principal Investigator: Laurence Belkoff
Phone: 610-667-0458
?
mi
from
Bala-Cynwyd, PA
Click here to add this to my saved trials
Birmingham, Alabama 35205
Principal Investigator: David Deatkine
Phone: 205-327-1077
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Birmingham, Alabama 35235
Principal Investigator: Gregory Flippo
Phone: 205-833-2228
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Birmingham, Alabama 35235
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Boise, Idaho 83704
Principal Investigator: Brock McConnehey
Phone: 208-685-0600
?
mi
from
Boise, ID
Click here to add this to my saved trials
Bradenton, Florida
?
mi
from
Bradenton, FL
Click here to add this to my saved trials
Brandon, Florida 33511
Principal Investigator: Daniel Lorch
Phone: 813-657-1584
?
mi
from
Brandon, FL
Click here to add this to my saved trials
Chattanooga, Tennessee 37403
Principal Investigator: David Huffman
Phone: 423-265-3561
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Chestnut Hill, Massachusetts 02467
Principal Investigator: Abraham Morgantaler
Phone: 617-277-5000
?
mi
from
Chestnut Hill, MA
Click here to add this to my saved trials
Clearwater, Florida 33756
Principal Investigator: Miguel Trevino
Phone: 727-584-6368
?
mi
from
Clearwater, FL
Click here to add this to my saved trials
Columbus, Ohio 43213
Principal Investigator: Samir Arora
Phone: 614-501-6164
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Garden City, New York 11530
Principal Investigator: Mitchell Efros
Phone: 516-746-2190
?
mi
from
Garden City, NY
Click here to add this to my saved trials
Houston, Texas 77062
Principal Investigator: Joe Pouzar
Phone: 281-282-0808
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77098
Principal Investigator: Francisco Velazquez
Phone: 713-333-9323
?
mi
from
Houston, TX
Click here to add this to my saved trials
Jupiter, Florida 33458
Principal Investigator: Ronald Surowitz
Phone: 561-741-2033
?
mi
from
Jupiter, FL
Click here to add this to my saved trials
Lake Charles, Louisiana 70601
Principal Investigator: Michael Seep
Phone: 337-433-3441
?
mi
from
Lake Charles, LA
Click here to add this to my saved trials
Lakeland, Florida 33805
Principal Investigator: James Andersen
Phone: 863-940-2087
?
mi
from
Lakeland, FL
Click here to add this to my saved trials
Las Vegas, Nevada 89102
Principal Investigator: Samer Nakhle
Phone: 702-736-5161
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Lexington, Kentucky 40509
Principal Investigator: Mark Adams
Phone: 859-264-8999
?
mi
from
Lexington, KY
Click here to add this to my saved trials
Meridian, Idaho 83642
Principal Investigator: Mark Turner
Phone: 208-377-8653
?
mi
from
Meridian, ID
Click here to add this to my saved trials
Miami, Florida 33155
Principal Investigator: Alfredo Suarez-Sarimento
Phone: 305-667-1080
?
mi
from
Miami, FL
Click here to add this to my saved trials
Mobile, Alabama 36608
Principal Investigator: Charles White
Phone: 251-414-1984
?
mi
from
Mobile, AL
Click here to add this to my saved trials
Mount Pleasant, South Carolina 29464
Principal Investigator: Cynthia Strout
Phone: 843-856-3784
?
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
Nashville, Tennessee 37203
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New York, New York 10016
Principal Investigator: Jed Kaminetsky
Phone: 212-480-3333
?
mi
from
New York, NY
Click here to add this to my saved trials
10040 Regency Cir
Omaha, Nebraska 68114
(402) 934-0044
Principal Investigator: David Jasper
Phone: 402-934-0044
Quality Clinical Research, Inc. Welcome to Quality Clinical Research. We originated here in Omaha, NE...
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Oviedo, Florida 32765
Principal Investigator: Craig Chase
Phone: 407-977-2705
?
mi
from
Oviedo, FL
Click here to add this to my saved trials
Renton, Washington 98057
Principal Investigator: Leslie Klaff
Phone: 425-251-1720
?
mi
from
Renton, WA
Click here to add this to my saved trials
Richland, Washington 99352
Principal Investigator: Lucien Megna
Phone: 509-420-5053
?
mi
from
Richland, WA
Click here to add this to my saved trials
Richmond, Virginia 23294
Principal Investigator: Keith Scott
Phone: 804-671-2133
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Saint Petersburg, Florida 33709
Principal Investigator: Gigi Lefebvre
Phone: 727-347-8839
?
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
San Diego, California 92120
Principal Investigator: Irwin Goldstein
Phone: 619-265-8865
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Tucson, Arizona 85712
Principal Investigator: John McGettigan
Phone: 520-495-5073
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
West Jordan, Utah 84088
Principal Investigator: Judith Kirstein
Phone: 801-542-8190
?
mi
from
West Jordan, UT
Click here to add this to my saved trials